Literature DB >> 31745296

Aberrant granulosa cell-fate related to inactivated p53/Rb signaling contributes to granulosa cell tumors and to FOXL2 downregulation in the mouse ovary.

Victoria Cluzet1, Marie M Devillers1, Florence Petit1, Stéphanie Chauvin1, Charlotte M François1, Frank Giton2, Catherine Genestie3, Nathalie di Clemente4, Joëlle Cohen-Tannoudji1, Céline J Guigon5,6.   

Abstract

Ovarian granulosa cell tumors (GCTs) are indolent tumors of the ovary affecting women at all ages and potentially displaying late recurrence. Even if there is still little information regarding the mechanisms involved in GCT development and progression, FOXL2 would be a major tumor suppressor gene in granulosa cells. We analyzed the mechanisms underlying GCT initiation and progression by using mice with targeted expression of SV40 large T-antigen in granulosa cells (AT mouse), which develop GCTs. Consistent with patients, AT mice with developing GCTs displayed increased levels in circulating anti-Müllerian hormone (AMH), estradiol and androgens, as well as decreased FOXL2 protein abundance. Very few mice developed metastases (1 out of 30). In situ analyses revealed that GCT initiation resulted from both increased granulosa cell survival and proliferation in large antral follicles. Tumorigenesis was associated with the combined inactivation of p53 and Rb pathways, as shown by the impaired expression of respective downstream targets regulating cell apoptosis and proliferation, i.e., Bax, Bak, Gadd45a, Ccna2, Ccne1, E2f1, and Orc1. Importantly, the expression of FOXL2 was still present in newly developed GCTs and its downregulation only started during GCT growth. Collectively, our experiments provide evidence that disrupted p53/Rb signaling can drive tumor initiation and growth. This model challenges the current paradigm that impaired FOXL2 signaling is a major switch of granulosa cell tumorigenesis, albeit possibly contributing to tumor growth.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31745296     DOI: 10.1038/s41388-019-1109-7

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  46 in total

1.  Transcription factor FOXL2 protects granulosa cells from stress and delays cell cycle: role of its regulation by the SIRT1 deacetylase.

Authors:  Bérénice A Benayoun; Adrien B Georges; David L'Hôte; Noora Andersson; Aurélie Dipietromaria; Anne-Laure Todeschini; Sandrine Caburet; Claude Bazin; Mikko Anttonen; Reiner A Veitia
Journal:  Hum Mol Genet       Date:  2011-02-02       Impact factor: 6.150

2.  Mutation of FOXL2 in granulosa-cell tumors of the ovary.

Authors:  Sohrab P Shah; Martin Köbel; Janine Senz; Ryan D Morin; Blaise A Clarke; Kimberly C Wiegand; Gillian Leung; Abdalnasser Zayed; Erika Mehl; Steve E Kalloger; Mark Sun; Ryan Giuliany; Erika Yorida; Steven Jones; Richard Varhol; Kenneth D Swenerton; Dianne Miller; Philip B Clement; Colleen Crane; Jason Madore; Diane Provencher; Peter Leung; Anna DeFazio; Jaswinder Khattra; Gulisa Turashvili; Yongjun Zhao; Thomas Zeng; J N Mark Glover; Barbara Vanderhyden; Chengquan Zhao; Christine A Parkinson; Mercedes Jimenez-Linan; David D L Bowtell; Anne-Marie Mes-Masson; James D Brenton; Samuel A Aparicio; Niki Boyd; Martin Hirst; C Blake Gilks; Marco Marra; David G Huntsman
Journal:  N Engl J Med       Date:  2009-06-10       Impact factor: 91.245

3.  DICER1 and FOXL2 mutations in ovarian sex cord-stromal tumours: a GINECO Group study.

Authors:  Thibault Goulvent; Isabelle Ray-Coquard; Stéphane Borel; Véronique Haddad; Mojgan Devouassoux-Shisheboran; Marie-Cecile Vacher-Lavenu; Eric Pujade-Laurraine; Ariel Savina; Denis Maillet; Germain Gillet; Isabelle Treilleux; Ruth Rimokh
Journal:  Histopathology       Date:  2015-07-21       Impact factor: 5.087

Review 4.  Molecular pathogenesis of granulosa cell tumors of the ovary.

Authors:  Stacey Jamieson; Peter J Fuller
Journal:  Endocr Rev       Date:  2012-01-12       Impact factor: 19.871

5.  FOXL2 C402G mutation detection using MALDI-TOF-MS in DNA extracted from Israeli granulosa cell tumors.

Authors:  Rotem Gershon; Sarit Aviel-Ronen; Jacob Korach; Vered Daniel-Carmi; Camila Avivi; Dalia Bar-Ilan; Iris Barshack; Dror Meirow; Gilad Ben-Baruch; Yoram Cohen
Journal:  Gynecol Oncol       Date:  2011-09       Impact factor: 5.482

Review 6.  Initial and cyclic recruitment of ovarian follicles.

Authors:  E A McGee; A J Hsueh
Journal:  Endocr Rev       Date:  2000-04       Impact factor: 19.871

7.  Extinction of FOXL2 expression in aggressive ovarian granulosa cell tumors in children.

Authors:  Nicolas Kalfa; Pascal Philibert; Catherine Patte; Aude Ecochard; Pierre Duvillard; Pierre Baldet; Francis Jaubert; Marc Fellous; Charles Sultan
Journal:  Fertil Steril       Date:  2007-04       Impact factor: 7.329

Review 8.  FOXL2: a central transcription factor of the ovary.

Authors:  Adrien Georges; Aurelie Auguste; Laurianne Bessière; Anne Vanet; Anne-Laure Todeschini; Reiner A Veitia
Journal:  J Mol Endocrinol       Date:  2013-12-19       Impact factor: 5.098

Review 9.  Granulosa cell tumor of the ovary.

Authors:  D Pectasides; E Pectasides; A Psyrri
Journal:  Cancer Treat Rev       Date:  2007-10-22       Impact factor: 12.111

10.  Antimüllerian hormone as a serum marker of granulosa cell tumorsof the ovary: comparative study with serum alpha-inhibin and estradiol.

Authors:  R A Rey; C Lhommé; I Marcillac; N Lahlou; P Duvillard; N Josso; J M Bidart
Journal:  Am J Obstet Gynecol       Date:  1996-03       Impact factor: 8.661

View more
  2 in total

1.  Whole Genome Analysis of Ovarian Granulosa Cell Tumors Reveals Tumor Heterogeneity and a High-Grade TP53-Specific Subgroup.

Authors:  Joline Roze; Glen Monroe; Joachim Kutzera; Jolijn Groeneweg; Ellen Stelloo; Sterre Paijens; Hans Nijman; Hannah van Meurs; Luc van Lonkhuijzen; Jurgen Piek; Christianne Lok; Geertruida Jonges; Petronella Witteveen; René Verheijen; Gijs van Haaften; Ronald Zweemer
Journal:  Cancers (Basel)       Date:  2020-05-21       Impact factor: 6.639

Review 2.  Estradiol Signaling at the Heart of Folliculogenesis: Its Potential Deregulation in Human Ovarian Pathologies.

Authors:  Stéphanie Chauvin; Joëlle Cohen-Tannoudji; Céline J Guigon
Journal:  Int J Mol Sci       Date:  2022-01-03       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.